NCT05564377 2026-03-18
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
9 trialsNCT06126276 2026-03-18
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT04886531 2026-03-12
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT06109467 2026-02-09
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT01494662 2026-01-23
HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03289039 2026-01-22
Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT05933395 2026-01-20
GERTRUDE
Dartmouth-Hitchcock Medical Center
Phase 2 Recruiting
NCT04374305 2026-01-12
INTUITT-NF2
Massachusetts General Hospital
Phase 2 Active not recruiting